La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Rhinomed Croissance future

Future contrôle des critères 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Rhinomed.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	28.4%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Rhinomed n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

ASX:RNO - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2023	8	-11	-7	-7	N/A
3/31/2023	9	-9	-7	-7	N/A
12/31/2022	9	-7	-7	-6	N/A
9/30/2022	10	-6	-7	-6	N/A
6/30/2022	10	-5	-7	-6	N/A
3/31/2022	8	-6	-6	-5	N/A
12/31/2021	6	-6	-5	-5	N/A
9/30/2021	5	-8	-5	-5	N/A
6/30/2021	4	-9	-5	-5	N/A
3/31/2021	5	-8	-5	-5	N/A
12/31/2020	5	-7	-4	-4	N/A
9/30/2020	5	-7	-5	-5	N/A
6/30/2020	4	-7	-6	-6	N/A
3/31/2020	4	-8	-6	-6	N/A
12/31/2019	4	-8	-6	-6	N/A
9/30/2019	4	-7	-5	-5	N/A
6/30/2019	3	-6	-5	-4	N/A
3/31/2019	3	-5	-4	-4	N/A
12/31/2018	3	-5	-4	-4	N/A
9/30/2018	3	-5	-4	-4	N/A
6/30/2018	2	-4	-4	-4	N/A
3/31/2018	2	-4	-3	-3	N/A
12/31/2017	1	-5	-3	-3	N/A
9/30/2017	2	-5	-3	-3	N/A
6/30/2017	2	-4	-3	-3	N/A
3/31/2017	2	-5	N/A	-4	N/A
12/31/2016	2	-5	N/A	-5	N/A
9/30/2016	1	-5	N/A	-6	N/A
6/30/2016	1	-6	N/A	-6	N/A
3/31/2016	1	-6	N/A	-6	N/A
12/31/2015	1	-6	N/A	-6	N/A
9/30/2015	1	-6	N/A	-5	N/A
6/30/2015	0	-5	N/A	-4	N/A
3/31/2015	0	-5	N/A	-4	N/A
12/31/2014	0	-5	N/A	-3	N/A
9/30/2014	0	-4	N/A	-3	N/A
6/30/2014	0	-4	N/A	-2	N/A
3/31/2014	0	-4	N/A	-2	N/A
12/31/2013	0	-4	N/A	-2	N/A
9/30/2013	0	-9	N/A	-2	N/A
6/30/2013	0	-15	N/A	-2	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if RNO's forecast earnings growth is above the savings rate (2.2%).

Bénéfices vs marché: Insufficient data to determine if RNO's earnings are forecast to grow faster than the Australian market

Croissance élevée des bénéfices: Insufficient data to determine if RNO's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: Insufficient data to determine if RNO's revenue is forecast to grow faster than the Australian market.

Croissance élevée des revenus: Insufficient data to determine if RNO's revenue is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if RNO's Return on Equity is forecast to be high in 3 years time

Rhinomed Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance